BeiGene/BMS Parting Abraxane Ways As China Supply Woes Continue
Competitive Landscape Also Changing
The latest development over the licensing arrangement for the anticancer drug may deal a further blow to BeiGene’s oncology commercial efforts in China.
You may also be interested in...
After winning a major procurement contract, BeiGene now may need to find an alternative manufacturing site for Celgene's Abraxane to supply China.
To ensure the Beijing Winter Olympics is a smooth affair, the Chinese government has ordered partial or complete halts in industrial production in some provinces from late November until mid-March, disrupting an already fragile global pharma active ingredient supply chain. The emergence of the Omicron coronavirus variant is just adding to the complexities.
Chinese firm BeyondSpring dealt a setback after the US FDA refuses to approve plinabulin for chemotherapy-induced neutropenia.